Incidence of Cancer of the Liver and Intrahepatic Bile Duct by County, New Mexico, 2017-2021
Indicator Report Data View Options
Incidence of Cancer of the Liver and Intrahepatic Bile Duct by County, New Mexico, 2017-2021
Why Is This Important?
Primary liver cancer (cancer that starts in the liver) accounts for over 2% of all new cancer cases and 5% of all cancer deaths in the U.S, which represents approximately 41,260 cases and 30,520 deaths. The five-year survival rate is 21%. Disease risk among males is about 3 times higher than that in females, reflecting a gender difference in risk factors that include alcohol abuse, chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), exposure to aflatoxin, and obesity. HBV and HCV can be spread from person to person through sharing contaminated needles (such as in drug use) or unprotected sex. Given these major risk factors, many cases of liver cancer are considered to be preventable.
Definition
Liver and intrahepatic bile duct cancer incidence refers to the number of persons newly diagnosed with liver and intrahepatic bile duct cancer during a specified time period. Measures include 1) age-adjusted incidence rate of liver and intrahepatic bile duct cancer (adjusted by the direct method to the 2000 US standard population and 2) age-adjusted incidence rates by race/ethnicity. All rates are expressed per 100,000 persons.
Data Notes
Rates have been age-adjusted using the direct method and the 2000 U.S. standard population. For more information on age-adjustment, please visit [https://ibis.doh.nm.gov/resource/AARate.html the NM-IBIS page on age-adjustment].Data Sources
- New Mexico Population Estimates: University of New Mexico, Geospatial and Population Studies (GPS) Program.
(http://gps.unm.edu/) - New Mexico Tumor Registry
(https://nmtrweb.unm.edu/)
How the Measure is Calculated
Numerator:
The number of liver and intrahepatic bile duct cancer cases newly diagnosed in New Mexico residents within a specified time period. The data are based on the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program incidence site recode for liver cancer (SEER Recode B 21071, 21072); ICD-O-3 codes: primary sites C220, C221; excludes histologies: 9590-9989, and 9140; Malignant cases: ICD behavior code 3.Denominator:
The estimated population of New Mexico residents within a specified time period.
Data Issues
New Mexico Population Estimates
{{class RedText NOTE: On January 16, 2025, the NM-IBIS and NMTracking POPULATION ESTIMATES FOR YEARS **2010 THROUGH 2023** WERE REPLACED. Data from the 2020 decennial census were used to update the estimates. Rates calculated using the NM-IBIS and NMTracking web-based queries are affected. Any rates that use population denominators that were calculated after January 16, 2025 will be different from those calculated prior to that date. We apologize for the inconvenience.}} All population estimates apply to July 1 of the selected year. These estimates are considered the most accurate estimates for the state of New Mexico and should match those found on the University of New Mexico [https://gps.unm.edu/pop/population-estimates.html Geospatial and Population Studies website]. Estimates include decimal fractions. Census tract population estimates were summed to produce County estimates. Population estimate totals may vary slightly due to rounding.
New Mexico Tumor Registry
In agreement with the New Mexico Tumor Registry, to ensure confidentiality the count of cancer cases is suppressed for any given county if the count is between one and four and the population is less than 1,000. NOTE: The COVID-19 pandemic disrupted health services, leading to delays and reductions in cancer screening, diagnosis, and reporting to some central cancer registries. This may have contributed to an observed decline in 2020 incidence for most cancer sites.